Magalashvili D, Mandel M, Dreyer-Alster S, Didikin M, et al. Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. J Neuroimmunol 2022;372:577966.
PMID: 36162338